Physician profile
Nicholas C Kolinsky
NPI 1033569439
$472,397.21
in general payments reported to CMS, 2019-2025
46 companies · $261K in 2025
The $261K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,296 · 2020: $2,008 · 2021: $2,600 · 2022: $4,454 · 2023: $9,519 · 2024: $190K · 2025: $261K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $386K · Food and Beverage: $26K · Travel and Lodging: $23K · Consulting Fee: $20K · Honoraria: $6,158 · Education: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $385,806.80 |
| Food and Beverage | $25,786.37 |
| Travel and Lodging | $22,689.53 |
| Consulting Fee | $20,097.78 |
| Honoraria | $6,158.00 |
| Education | $502.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $319,429.62 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $35,735.15 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $26,795.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $21,252.60 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Ionis Pharmaceuticals, INC. | $18,541.11 | 2025 | Dawnzera |
| Genzyme Corporation | $8,599.91 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $7,526.16 | 2021-2025 | |
| Hikma Pharmaceuticals USA | $6,251.34 | 2024-2025 | Ryaltris |
| Grifols USA, LLC | $4,897.53 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Blueprint Medicines Corporation | $4,472.75 | 2022-2025 | Ayvakit |
| Adma Biomanufacturing LLC | $3,566.82 | 2022-2025 | |
| Pharming Healthcare, INC. | $2,999.33 | 2021-2025 | Joenja, Ruconest |
| Amgen INC. | $2,643.30 | 2019-2025 | Tezspire |
| Incyte Corporation | $2,256.62 | 2025 | Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $1,335.32 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols Shared Services North America, INC. | $1,327.50 | 2025 | Xembify |
| Genentech USA, INC. | $1,038.09 | 2019-2025 | Xolair |
| Alk-Abello, INC | $838.92 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $286.93 | 2025 | Neffy |
| Lilly USA, LLC | $282.13 | 2024-2025 | Ebglyss, Taltz |
| Janssen Pharmaceuticals, INC | $217.00 | 2019-2020 | |
| Galderma Laboratories, L.P. | $204.66 | 2025 | Nemluvio |
| Optinose US, INC. | $163.01 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $154.67 | 2022-2023 | Airduo Digihaler |
| Kaleo, INC. | $145.01 | 2022-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $140.75 | 2021-2025 | Orladeyo |
| Pfizer INC. | $134.66 | 2022-2025 | |
| Abbvie INC. | $129.90 | 2022 | |
| Portola Pharmaceuticals, LLC | $124.82 | 2020 | |
| Pulmonx Corporation | $121.43 | 2021 | |
| Merck Sharp & Dohme LLC | $114.45 | 2019 | |
| Therapeuticsmd, INC. | $110.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Verona Pharma, INC. | $99.01 | 2025 | Ohtuvayre |
| Shire North American Group INC | $60.57 | 2019 | |
| Octapharma USA, INC. | $53.56 | 2023 | Cutaquig |
| Paratek Pharmaceuticals, INC. | $37.29 | 2025 | Xhance |
| Organon LLC | $30.59 | 2025 | |
| Genentech, INC. | $30.01 | 2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.24 | 2021-2022 | |
| Hospira, INC. | $22.93 | 2024 | |
| Gc Biopharma USA, INC. | $22.84 | 2025 | Alyglo |
| X4 Pharmaceuticals, INC. | $21.71 | 2024 | Xolremdi |
| Arcutis Biotherapeutics, INC. | $17.96 | 2025 | Zoryve |
| Inogen, INC. | $17.65 | 2023 | Inogen At Home Stationary Concentrator |
| Mylan Specialty L.P. | $16.77 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kolinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.